CA2534996A1 - Utilisation du silencage sirna dans la prevention des metastases - Google Patents

Utilisation du silencage sirna dans la prevention des metastases Download PDF

Info

Publication number: CA2534996A1
Authority: CA; Canada
Prior art keywords: sirna; seq; use according; cells; sirnas
Prior art date: 2003-08-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002534996A

Other languages

English (en)

Inventor

Hans Prydz

Mohammed Amarzguioui

Torgeir Holen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SIRNASENSE AS

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-06

Filing date

2004-08-05

Publication date

2005-05-06

2003-08-06 Priority claimed from NO20033492A external-priority patent/NO20033492D0/no

2004-08-05 Application filed by Individual filed Critical Individual

2005-05-06 Publication of CA2534996A1 publication Critical patent/CA2534996A1/fr

Status Abandoned legal-status Critical Current

Links

206010027476 Metastases Diseases 0.000 title claims abstract description 48
230000009401 metastasis Effects 0.000 title claims abstract description 47
230000002265 prevention Effects 0.000 title claims abstract description 12
230000006807 siRNA silencing Effects 0.000 title description 5
108020004459 Small interfering RNA Proteins 0.000 claims abstract description 318
108010000499 Thromboplastin Proteins 0.000 claims abstract description 173
102000002262 Thromboplastin Human genes 0.000 claims abstract description 172
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 78
108020004999 messenger RNA Proteins 0.000 claims description 66
239000002773 nucleotide Substances 0.000 claims description 43
125000003729 nucleotide group Chemical group 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 35
150000007523 nucleic acids Chemical group 0.000 claims description 28
239000004055 small Interfering RNA Substances 0.000 claims description 22
241000282414 Homo sapiens Species 0.000 claims description 19
230000000295 complement effect Effects 0.000 claims description 18
238000009472 formulation Methods 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 16
238000003776 cleavage reaction Methods 0.000 claims description 15
230000007017 scission Effects 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 12
108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
238000001990 intravenous administration Methods 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
239000002671 adjuvant Substances 0.000 claims description 6
239000000443 aerosol Substances 0.000 claims description 6
239000012634 fragment Substances 0.000 claims description 6
238000001802 infusion Methods 0.000 claims description 6
238000007920 subcutaneous administration Methods 0.000 claims description 6
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
238000010521 absorption reaction Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
238000007918 intramuscular administration Methods 0.000 claims description 5
239000007927 intramuscular injection Substances 0.000 claims description 5
239000007928 intraperitoneal injection Substances 0.000 claims description 5
239000000829 suppository Substances 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000007921 spray Substances 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
238000004040 coloring Methods 0.000 claims description 3
239000000796 flavoring agent Substances 0.000 claims description 3
235000003599 food sweetener Nutrition 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000006187 pill Substances 0.000 claims description 3
238000013268 sustained release Methods 0.000 claims description 3
239000012730 sustained-release form Substances 0.000 claims description 3
239000003765 sweetening agent Substances 0.000 claims description 3
239000003981 vehicle Substances 0.000 claims description 3
239000003978 infusion fluid Substances 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 abstract description 64
230000014509 gene expression Effects 0.000 abstract description 62
102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 40
238000011282 treatment Methods 0.000 abstract description 20
201000011510 cancer Diseases 0.000 abstract description 15
210000004027 cell Anatomy 0.000 description 113
230000000694 effects Effects 0.000 description 76
230000009368 gene silencing by RNA Effects 0.000 description 44
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 41
238000000034 method Methods 0.000 description 37
108091034117 Oligonucleotide Proteins 0.000 description 31
108090000623 proteins and genes Proteins 0.000 description 30
230000035772 mutation Effects 0.000 description 27
238000001890 transfection Methods 0.000 description 27
238000003556 assay Methods 0.000 description 26
239000007924 injection Substances 0.000 description 26
238000002347 injection Methods 0.000 description 26
241000699670 Mus sp. Species 0.000 description 25
150000003839 salts Chemical class 0.000 description 24
238000002474 experimental method Methods 0.000 description 23
101000635804 Homo sapiens Tissue factor Proteins 0.000 description 22
230000030279 gene silencing Effects 0.000 description 22
238000012986 modification Methods 0.000 description 21
108091027967 Small hairpin RNA Proteins 0.000 description 20
230000004048 modification Effects 0.000 description 20
-1 genomic Proteins 0.000 description 18
102000039446 nucleic acids Human genes 0.000 description 18
108020004707 nucleic acids Proteins 0.000 description 18
239000002253 acid Substances 0.000 description 17
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
108010002380 serum tumorlytic factor Proteins 0.000 description 16
230000001404 mediated effect Effects 0.000 description 15
206010053567 Coagulopathies Diseases 0.000 description 13
108020004414 DNA Proteins 0.000 description 13
239000002585 base Substances 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
230000008685 targeting Effects 0.000 description 13
238000006731 degradation reaction Methods 0.000 description 12
210000004962 mammalian cell Anatomy 0.000 description 12
241000124008 Mammalia Species 0.000 description 11
230000000692 anti-sense effect Effects 0.000 description 11
230000015556 catabolic process Effects 0.000 description 11
108060001084 Luciferase Proteins 0.000 description 10
239000005089 Luciferase Substances 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
210000004072 lung Anatomy 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
239000002777 nucleoside Substances 0.000 description 9
230000008569 process Effects 0.000 description 9
241000894007 species Species 0.000 description 9
239000013598 vector Substances 0.000 description 9
108090000994 Catalytic RNA Proteins 0.000 description 8
102000053642 Catalytic RNA Human genes 0.000 description 8
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 8
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
230000001394 metastastic effect Effects 0.000 description 8
230000032361 posttranscriptional gene silencing Effects 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108091092562 ribozyme Proteins 0.000 description 8
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
208000001382 Experimental Melanoma Diseases 0.000 description 7
102000006382 Ribonucleases Human genes 0.000 description 7
108010083644 Ribonucleases Proteins 0.000 description 7
230000033115 angiogenesis Effects 0.000 description 7
230000035602 clotting Effects 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
230000003211 malignant effect Effects 0.000 description 7
206010061289 metastatic neoplasm Diseases 0.000 description 7
230000037361 pathway Effects 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
108091081021 Sense strand Proteins 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
208000015294 blood coagulation disease Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000009852 coagulant defect Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
238000003197 gene knockdown Methods 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
125000003835 nucleoside group Chemical group 0.000 description 6
230000002947 procoagulating effect Effects 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
241000283690 Bos taurus Species 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000012226 gene silencing method Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
230000002688 persistence Effects 0.000 description 5
229910052698 phosphorus Inorganic materials 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
108091093037 Peptide nucleic acid Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
241000282485 Vulpes vulpes Species 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
230000023555 blood coagulation Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
229940104302 cytosine Drugs 0.000 description 4
230000009977 dual effect Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000003306 harvesting Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
239000006166 lysate Substances 0.000 description 4
210000001161 mammalian embryo Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
150000003833 nucleoside derivatives Chemical class 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
125000004437 phosphorous atom Chemical group 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
230000001603 reducing effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
229930024421 Adenine Natural products 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
102100023804 Coagulation factor VII Human genes 0.000 description 3
239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 3
108010023321 Factor VII Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
108090001102 Hammerhead ribozyme Proteins 0.000 description 3
239000012097 Lipofectamine 2000 Substances 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
230000004075 alteration Effects 0.000 description 3
150000001408 amides Chemical group 0.000 description 3
210000003484 anatomy Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000007820 coagulation assay Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000037440 gene silencing effect Effects 0.000 description 3
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
208000037841 lung tumor Diseases 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000012545 processing Methods 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
125000002652 ribonucleotide group Chemical group 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
241000255601 Drosophila melanogaster Species 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
101710203526 Integrase Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
206010027458 Metastases to lung Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000244206 Nematoda Species 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
239000012124 Opti-MEM Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
241000251131 Sphyrna Species 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
241001150496 Tosapusia duplex Species 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000002257 antimetastatic agent Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
229940012413 factor vii Drugs 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
239000000174 gluconic acid Substances 0.000 description 2
235000012208 gluconic acid Nutrition 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000003999 initiator Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000010841 mRNA extraction Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920000768 polyamine Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
239000012096 transfection reagent Substances 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical compound OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
229960005508 8-azaguanine Drugs 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
235000003332 Ilex aquifolium Nutrition 0.000 description 1
241000209027 Ilex aquifolium Species 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101710141452 Major surface glycoprotein G Proteins 0.000 description 1
241001599018 Melanogaster Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
241000009328 Perro Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010052090 Renilla Luciferases Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000005600 alkyl phosphonate group Chemical group 0.000 description 1
238000005937 allylation reaction Methods 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
125000005122 aminoalkylamino group Chemical group 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000002787 antisense oligonuctleotide Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
230000004087 circulation Effects 0.000 description 1
HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000007819 clotting time assay Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229940105772 coagulation factor vii Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000005712 elicitor Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000004049 epigenetic modification Effects 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000006203 ethylation Effects 0.000 description 1
238000006200 ethylation reaction Methods 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000006624 extrinsic pathway Effects 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000003862 health status Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical group 0.000 description 1
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
108091092021 miR-2150 stem-loop Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000008742 procoagulation Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000001743 silencing effect Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000001324 spliceosome Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
150000003456 sulfonamides Chemical group 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003457 sulfones Chemical group 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
101150003485 unc-22 gene Proteins 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002534996A 2003-08-06 2004-08-05 Utilisation du silencage sirna dans la prevention des metastases Abandoned CA2534996A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
NO20033492		2003-08-06
NO20033492A NO20033492D0 (no)	2003-08-06	2003-08-06	Bruk av siRNA i avstengning av gener for å hindre utvikling av metastaser
US49731403P	2003-08-25	2003-08-25
US60/497,314		2003-08-25
PCT/NO2004/000238 WO2005040187A2 (fr)	2003-08-06	2004-08-05	Utilisation du silençage sirna dans la prevention des metastases

Publications (1)

Publication Number	Publication Date
CA2534996A1 true CA2534996A1 (fr)	2005-05-06

Family

ID=34525618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002534996A Abandoned CA2534996A1 (fr)	2003-08-06	2004-08-05	Utilisation du silencage sirna dans la prevention des metastases

Country Status (5)

Country	Link
EP (1)	EP1660658A2 (fr)
JP (1)	JP2007501225A (fr)
AU (1)	AU2004284013A1 (fr)
CA (1)	CA2534996A1 (fr)
WO (1)	WO2005040187A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2397851T3 (es)	2005-07-13	2013-03-11	Novo Nordisk Health Care Ag	Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002514201A (ja) *	1997-01-22	2002-05-14	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	凝固および腫瘍の処置のための組織因子の方法および組成物
BR0012408A (pt) *	1999-07-14	2002-03-12	Novo Nordisk As	Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido
ATE449846T1 (de) *	2002-02-07	2009-12-15	Sirnasense As	Post-transcriptional silencing der gewebefaktor expression durch kurze interferierende rnas
US20050096289A1 (en) *	2002-02-07	2005-05-05	Hans Prydz	Methods and compositions for modulating tissue factor

2004
- 2004-08-05 WO PCT/NO2004/000238 patent/WO2005040187A2/fr active Search and Examination
- 2004-08-05 JP JP2006522519A patent/JP2007501225A/ja active Pending
- 2004-08-05 EP EP04816701A patent/EP1660658A2/fr not_active Withdrawn
- 2004-08-05 AU AU2004284013A patent/AU2004284013A1/en not_active Abandoned
- 2004-08-05 CA CA002534996A patent/CA2534996A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
AU2004284013A1 (en)	2005-05-06
WO2005040187A2 (fr)	2005-05-06
WO2005040187A3 (fr)	2005-09-01
JP2007501225A (ja)	2007-01-25
EP1660658A2 (fr)	2006-05-31

Legal Events

Date	Code	Title	Description
2009-08-04	EEER	Examination request
2012-08-06	FZDE	Dead

Publication	Publication Date	Title
AU2019200789B2 (en)	2021-04-01	Multimeric oligonucleotide compounds
KR101770435B1 (ko)	2017-09-05	자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료
JP5362350B2 (ja)	2013-12-11	小分子活性化ｒｎａ分子及び使用方法
KR101829469B1 (ko)	2018-03-30	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR101718297B1 (ko)	2017-03-20	Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
EP3573623A1 (fr)	2019-12-04	Compositions et méthodes d'inhibition de l'expression génique du facteur xii
US20160272970A1 (en)	2016-09-22	RNA Interference Agents
KR20200044013A (ko)	2020-04-28	아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
AU2003258183B2 (en)	2009-03-26	Use of antisense oligonucleotides to inhibit the expression of Akt-1
US20050153918A1 (en)	2005-07-14	Methods and compositions relating to hnRNP A1, A1B, A2, and B1 nucleic acid molecules
JP2007510408A (ja)	2007-04-26	Ｉａｐ核酸塩基オリゴマーおよび核酸塩基オリゴマー複合体ならびにそれらの使用
TW201918555A (zh)	2019-05-16	用於抑制去唾液酸醣蛋白受體1表現之RNAi試劑及組合物
WO2011054939A2 (fr)	2011-05-12	Compositions et procédés pour inhiber l'expression de gènes kif10
US20100273998A1 (en)	2010-10-28	Methods and compositions for modulating tissue factor
EP1601325A2 (fr)	2005-12-07	Oligonucleotides anti-sens inhibant l'expression du hif-1
CA2534996A1 (fr)	2005-05-06	Utilisation du silencage sirna dans la prevention des metastases
AU2003206267B2 (en)	2008-10-02	Short interfering RNA molecules directed towards a tissue factor coding nucleic acid
JP4546454B2 (ja)	2010-09-15	Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CN111107853B (zh)	2024-07-30	用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
OA19513A (en)	2020-11-13	RNAI agents and compositions for inhibiting expression of apolipoprotein C-lll (APOC3).
WO2008106796A1 (fr)	2008-09-12	Induction d'apoptose et inhibition de prolifération cellulaire par modulation de l'activité carnitine palmitoyltransférase 1c